Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials

Amirhossein Sahebkar, L.E. Simental-Mendía, F. Guerrero-Romero, J. Golledge, Gerald Watts

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

© 2015 John Wiley & Sons Ltd. Aims: To evaluate the magnitude of the effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) levels through a systematic review and meta-analysis of clinical trials. Methods: A random-effects model (using DerSimonian-Laird method) and the generic inverse variance method were used for quantitative data synthesis. Heterogeneity was quantitatively assessed using the I2 index. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed using an unrestricted maximum likelihood method to evaluate the association between statin-induced elevation of plasma PCSK9 concentrations with duration of treatment and magnitude of LDL cholesterol reduction. Results: A total of 15 clinical trials examining the effects of statin therapy on plasma PCSK9 levels were included. Meta-analysis of data from single-arm statin treatment arms [weighted mean difference (WMD) 40.72ng/ml, 95% confidence interval (CI) 34.79, 46.65; p
Original languageEnglish
Pages (from-to)1042-1055
JournalDiabetes, Obesity and Metabolism
Volume17
Issue number11
DOIs
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials'. Together they form a unique fingerprint.

  • Cite this